Latest Treatment News in Neuroendocrine Tumours
As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection) Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for [...]
68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have [...]
Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]
Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]
TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]
REQUEST FOR PATIENT INPUT - TREATMENT WITH Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera) Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera), is a peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues (peptides). [...]
Somatuline Autogel is the first and only somatostatin analog (SSA) approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome. Februaury 13th, 2018 - Health Canada announced the approval [...]
The Gallium 68 scan, used with functional PET imaging, is a nuclear medicine scan that relies on the over-expression of somatostatin receptors to visualize tumours. NETs typically express several somatostatin receptor subtypes in [...]
As we advised previously, in July of this year the Manitoba government issued a bulletin http://www.gov.mb.ca/health/mdbif/…/bulletins/bulletin93.pdf that indicated a change in the listing for Somatuline (from 1 to 3 and no access [...]